Meta-Analysis of the Effect of Aspirin on Mortality in COVID-19 Husam M. Salah, et al. Repurposing of existing medications has widely been used in studies since the emergence of coronavirus disease 2019 (COVID-19). Besides dexamethasone in selected patients, no medical treatment to date has been shown to improve mortality in patients with COVID-19 infection. Aspirin…
Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration Thomas F. Osborne et al. Abstract There is growing evidence that thrombotic and inflammatory pathways contribute to the severity of COVID-19. Common medications such as aspirin, that mitigate these pathways, may decrease COVID-19 mortality. This retrospective assessment was designed to quantify…
Global Incidence of Acute Pancreatitis Is Increasing Over Time: A Systematic Review and Meta-Analysis Jordan P. Iannuzzi et al. Background & Aims Acute pancreatitis is a common disease with significant associated morbidity and mortality. We performed a systematic review and meta-analysis of population-based studies to explore the changing temporal trends of acute pancreatitis incidence globally.…
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients Angélica Jayk Bernal et al. BACKGROUND New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS We conducted a phase 3, double-blind,…
Next-Generation Artificial Intelligence for Diagnosis From Predicting Diagnostic Labels to “Wayfinding” Julia Adler-Milstein et al. Improving the diagnostic process is a quality and safety priority.1 With the digitization of health records and rapid expansion of health data, the cognitive demand on the diagnostician has increased. The use of artificial intelligence (AI) to assist human cognition has…
Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor Laurène Parrot, et al. Summary Background Ustekinumab and vedolizumab are commonly used after anti-tumour necrosis factor (TNF) failure in patients with Crohn’s disease (CD). No randomised controlled trial has compared these drugs. Aims To…